Topic Listing for Cytomedix

Accounts Royalties Receivable Act
Adverse Conditions Global Economy Disruption Financial Markets Significantly Adversely Affected Customers Cannot Obtain Reimbursement
Affected Malpractice Claims Amend Long-term Incentive Plan Increase Number Shares Common
Annual Meeting Postponed Annual Meeting Shareholders 2008
Anti-inflammatory Peptide Applicable Only Corporate Issuers
Applicable Only Corporate Registrants Applicable Only Issuers Involved Bankruptcy Proceedings Preceding
Attend Meeting Audit Committee
Audit Committee Pre-approval Non-audit Services Audit Committee Pre-approval Policies Procedures
Audit Fees Tax Autologel Components Subject Governmental Regulation
Autologel Efficacy Studies Autologel Existing Competition Marketplace
Autologel System Autologel System Components Subject Governmental Regulation
Available Information Basis Presentation
Beneficial Ownership Compliance 2007 Beneficial Ownership Compliance 2008
Beneficial Ownership Reporting Compliance Beneficial Ownership Reporting Compliance 2006
Bio-pharmaceutical Product Regulation Biographical Information Directors Executive Officers
Biographies Current Directors Officers Board Directors
Board Directors Committees Board Directors Recommends Vote James Benson David Crews
Board Directors Recommends Vote Proposals Board Member Attendance Annual Meetings
Board Recommendation Breakdown Chronic Wound Market
Business Capital Stock Activity
Cash Equivalents Certain Numbers Been Rounded Ease Analysis
Certain Relationships Related Transactions Certain Relationships Related Transactions Director Independence
Certification Chief Executive Officer Pursuant Rule 13a-14 15d-14 Certification Chief Executive Officer Pursuant Usc Ss1350
Certification Chief Executive Officer Pursuant Usc §1350 Certification Chief Financial Officer Pursuant Rule 13a-14 15d-14
Certification Chief Financial Officer Pursuant Usc Ss1350 Certification Chief Financial Officer Pursuant Usc §1350
Changes Executive Management Changes Internal Control Over Financial Reporting
Chronic Wound Market Clinical Trial Data
Clinical Trial Fda Clearance Clinical Trial Related Expenses
Clinical Trials Fail Demonstrate Safety Efficacy Ct-112 Peptides Clinical Trials Fail Demonstrate Safety Efficacy Product Candidates
Cmss Non-coverage Autologel Greatly Restrict Sales Code Conduct Ethics
Commitments Contingencies Common Stock
Comparison Operating Results Periods 2007 2006 Comparison Operating Results Periods 2008 2007
Comparison Operating Results Periods 2009 2008 Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Directors Compensation Directors Executive Officers
Compensation Discussion Analysis Competition
Concentration Risk Conclusion Regarding Effectiveness Disclosure Controls Procedures
Consulting Expenses Consulting Expenses-related Party
Consulting Related Party Expenses Contemplated Additional Study Not Yield Sufficient Favorable Data
Contractual Obligations Control Number
Controls Procedures Corporate Overview
Cytomedix Cytomedix Inc
Cytomedix Inc 416 Hungerford Suite 330 Rockville Maryland Cytomedix Inc Name Registrant Specified Charter
Cytomedix Inc Notes Financial Statements Cytomedix Inc Proxy Solicited Behalf Board Directors Annual
Cytomedix Inc Table Contents Deferred Compensation
Defined Contribution Plans Description Business
Diabetic Foot Ulcers Did Send Proxy Statement
Director Board Nominee Independence Director Compensation
Director Compensation 2006 Director Compensation 2007
Director Independence Director Nominees
Directors Executive Officers Cytomedix Disclosure Controls Procedures
Disruption Healthcare Provider Networks Adverse Effect Operations Profitability Dissenters Rights Appraisal
Dividends Documents Incorporated Reference
Economic Study Elect Directors Each Serve Until Next Annual Meeting
Elements Compensation Employees
Employment Contracts Termination Change-in-control Arrangements Equity Compensation Plan Information 2006
Equity Compensation Plan Information 2007 Equity Compensation Plan Information 2008
Estimates Evaluation Disclosure Controls Procedures
Executive Compensation Philosophy Exhibits
Exhibits Financial Statement Schedules Explanatory
Extension Warrant Term Fair Value Financial Instruments
Fda Clearance Fda Clearance Clinical Trial Other Studies
Fda Denied Claims 510 Pre-market Notification Appeal Not Financial Information Segments Geographic Regions
Form 10-k Form 10-k Amendment
Form 10-q Form 10-q Amendment
Forward Looking Statements Forward-looking Information
Forward-looking Statements Fraud Abuse Laws
General General Administrative Expenses
General Development Business Government Approval
Government Regulation Government Regulation Approval
Grant Stock Options Grants Plan-based Awards 2007
Gross Profit Guarantee Able Obtain Fda Marketing Clearance Autologel
Guarantee Able Obtain Fda Marketing Clearance Autologeltm History Losses
Holders Impairment Goodwill Patents
Important Notice Regarding Internet Availability Proxy Materials 2009 Incidence Chronic Wounds
Income Taxes Incorporation Reference
Independent Public Accountants Independent Registered Public Accounting Firm Expressed Substantial Doubt
Index Inflation
Intangible Assets Intellectual Property Assets Critical Success
Intellectual Property Rights Intention Develop Plan Secure Medicare Reimbursement Without Conducting
Interest Certain Persons Matters Acted Inventory
Issuance Preferred Stock Dividends Issue Additional Equity Debt Securities Materially Adversely Affect
Issue Additional Equity Securities Materially Adversely Affect Price Legal Proceedings
Legislative Administrative Action Adverse Effect Limited Public Trading Market Common Stock
Limited Sources Working Capital Liquidity Capital Resources
Liquidity Risks Managements Plans Long Term Incentive Plan
Loss Per Share Lump-sum Payments Settlement Agreements
Making Solicitation Managements Report Internal Control Over Financial Reporting
Market Market Information
Market Registrants Common Equity Related Stockholder Matters Issuer Medical Device Regulation
Medicare Reimbursement Membership Meetings Attendance
Modified Ebitda Information Not Conformity Generally Accepted Accounting Named Executive Officers 2007
Narrative Disclosure Summary Compensation Grants Nominating Governance Committee
Non-reimbursement Sensitive Market Notes Financial Statements
Notice Annual Meeting Shareholders Held 2008 Notice Annual Meeting Shareholders Held 2009
Nyse Amex Approval Plan Compliance Nyse Amex Listing Deficiency Notification
Obtain Additional Information Cytomedix Off-balance Sheet Arrangements
Offerings Operating Expense Information Not Conformity Generally Accepted Accounting
Operating Expenses Operating Leases
Other Income Other Income Expenses
Other Information Other Initiatives
Other Markets Other Matters
Other Opportunities Other Patents
Overview Overview Audit Fees
Overview Business Overview Cytomedix Directors Executive Officers
Patent Amortization Patent Settlement License Agreements
Patents Patents Licenses Property Rights
Patents Licensing Performance Graph
Pre-approval Policies Prepaid Expenses Inventory Other Current Assets
Pressure Ulcers Principal Accounting Fees Services
Principal Executive Offices Cytomedix Professional Fees
Properties Property Equipment
Proposal Election Directors Proposal Ratification Appointment Independent Public Accountant
Prospects Future Proxy Properly Executed Voted Manner Directed Undersigned Shareholder
Proxy Solicited Behalf Board Directors Cytomedix Inc Proxy Statement Annual Meeting Shareholders
Proxy Statement Pursuant Securities Exchange Act 1934 Quantitative Qualitative Disclosures Market Risk
Quarterly Period 2006 Receivables
Recent Accounting Pronouncements Recent Changes Executive Management
Recent Sales Unregistered Securities Reclassification
Reclassifications References
Registration Payment Arrangements Reimbursement
Reimbursement Clearance Related Party Transactions
Remediation Efforts Remediation Initiatives
Report Audit Committee Report Independent Registered Public Accounting Firm
Research Development Restatement Financial Statements
Restatement Financial Statements Correction Error Restricted Cash Letter Credit
Restricted Short-term Investments Revenue Recognition
Revenues Review Approval Policies Procedures Related Party Transactions
Revoke Proxy Revoke Proxy After Return Card
Risk Economic Downturns Changes Risk Factors
Risks Related Common Stock Rockville 2009
Rockville 2009 8211 Cytomedix Inc Nyse Amex Gtf Royalty Agreements
Royalty Revenues Unpredictable Salaries Wages
Sales Marketing Sales Marketing Strategy Autologel System Not Succeed
Sales Non-reimbursement Sensitive Market Sec Comments
Securities Authorized Issuance Equity Compensation Plans Security Ownership Certain Beneficial Owners
Selected Financial Data Series Convertible Preferred Stock
Settlement License Agreements Shareholder Communications Directors
Shareholder Proposals Shareholder Proposals Submissions Inclusion Proxy Statement 2009 Annual
Shareholder Proposals Submissions Inclusion Proxy Statement 2010 Annual Shareholders Own Least Cytomedix
Shareholders Proxy Confidential Voting Instruction Card Annual Meeting Short Operating History Limited Experience
Short-term Investments Signatures
Source Advanced Wound Management Healing Restoring Lives Medical Statements Cash Flows
Stock-based Compensation Strategy
Subject Anti-takeover Provisions Laws Submission Matters Vote Security Holders
Subsequent Events Substantial Doubt Ability Continue Going Concern
Success Autologel System Dependent Acceptance Medical Community Summary
Summary Compensation Table 2006 Supervision Healthcare Professional Autologel System Suitable Exuding Wounds
Supplemental Cash Flow Disclosures Non-cash Transactions Suppliers
Table Contents Termination Consulting Agreement
Third-party Reimbursement Trials Studies
Unable Accurately Predict Royalty Revenues Unable Attract Retain Key Personnel
Unregistered Sales Equity Securities Proceeds Valuation Goodwill
Valuation Patents Venous Stasis Leg Ulcers
Vote Vote Directors
Vote Important Even Plan Attend Annual Meeting Encourage Vote Important Today Ways
Vote Person Vote Proposal
Vote Proxy Vote Required Approval Proposal
Votes What Purposes Meeting
What Vote Required Take Action Working Capital
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki